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Abstract: Selective serotonin reuptake inhibitors and selective norepinephrine reuptake 
inhibitors are effective in the treatment of bulimia nervosa. There have been relatively few stud-
ies of the efﬁ  cacy of speciﬁ  c serotonin and norepinephrine reuptake inhibitors in the treatment 
of eating disorders. Twenty-ﬁ  ve outpatients with binge eating episodes, diagnosed as anorexia 
nervosa, binge-eating/purging type, bulimia nervosa/purging type, or bulimia nervosa/non-purg-
ing type, were treated with milnacipran and 20 patients completed the 8-week study. Symptom 
severity was evaluated using the Bulimic Investigatory Test, Edinburgh (BITE) self-rating scale 
before administration of milnacipran and after 1, 4, and 8 weeks treatment. The scores improved 
after 8 weeks, especially drive to, and regret for, binge eating. Milnacipran was more effective in 
patients without purging and in younger patients, while there was no difference in the efﬁ  cacy 
of milnacipran among subtypes of eating disorders.
Keywords: milnacipran, speciﬁ  c serotonin and norepinephrine reuptake inhibitors, binge eat-
ing, vomiting, eating disorder, pharmacotherapy
Introduction
Many patients with eating disorders suffer from repeated episodes of binge eating, 
followed by inappropriate compensatory behaviors to prevent weight gain.
The discovery of disturbed brain serotonin activity in patients with bulimia 
nervosa (Jimerson et al 1992; Tauscher et al 2001) led to the use of selective serotonin 
reuptake inhibitors (SSRIs) for the treatment of patients with bulimic episodes even 
in the absence of depressive symptoms (Fichter et al 1996; Agras 1997; Romano et al 
2002; Milano et al 2004). Disturbed noradrenergic function has also been implicated 
in bulimia nervosa (Brambilla 2001) and the efﬁ  cacy of the selective norepinephrine 
reuptake inhibitor, reboxetine, in treating patients with bulimic episodes has been 
reported (El-Giamal et al 2000; Fassino et al 2004).
Thus speciﬁ  c serotonin and norepinephrine reuptake inhibitors (SNRIs) would be 
expected to be effective in the treatment of bulimic episodes in eating disorders and 
positive preliminary results have been reported with venlafaxine (Malhotra et al 2002) 
and duloxetine (Hazen and Fava 2006).
For milnacipran, the only SNRI currently available Japan, a pilot study (El-Giamal 
et al 2003) has reported the efﬁ  cacy of milnacipran on purging binge eating.
We describe here a study investigating the efﬁ  cacy of milnacipran in the treatment 
of binge eating in purging and non-purging patients.
Methods
Participants
Twenty-ﬁ  ve outpatients suffering from eating disorders with binge eating (APA 
1995), who were treated at the Kyoto University Hospital, Japan, from February 2004 
through December 2006, were included in the study. No participant suffered from any Neuropsychiatric Disease and Treatment 2008:4(1) 296
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psychiatric disorder other than eating disorders and none had 
previously taken any psychotropic medication.
The study, which was approved by the ethics committee 
of Kyoto University Hospital, was carried out in accordance 
with the Declaration of Helsinki and all participants gave 
their informed consent to participate in the study.
Psychometric instruments
Eating behavior including the frequency of binge eating and 
purging was assessed using the Bulimic Investigatory Test, 
Edinburgh (BITE) (Henderson and Freeman 1987). The BITE 
self-report questionnaire consists of 30 items of symptoms 
(BITE-symptom) and 6 items of severity (BITE-severity). 
The score of the BITE-symptom is the total number of “no” 
answers in items 1, 13, 21, 23, and 31 and “yes” answers in 
the other items. The BITE-severity score is the number of 6 
items present (fasting, taking diet pills, diuretics, and laxa-
tives, self-induced vomiting, and binge eating episodes). A 
Japanese version of the BITE and its validation have been 
published (Nakai et al 1998). The prevalence of depres-
sive and anxious symptoms was rated using the Hamilton 
Depression Rating Scale (HAM-D) (Hamilton 1960) and 
the Hamilton Anxiety Rating Scale (HAM-A) (Hamilton 
1959), respectively. The general condition and the degree of 
improvement was assessed using the Clinical Global Impres-
sion (CGI) (National Institute of Mental Health 1976).
Procedures
All subjects were assessed 4 times during the 8-week study 
using BITE, HAM-D, HAM-A, and CGI – at baseline prior 
to milnacipran administration and following 1 week, 4 weeks, 
and 8 weeks of drug administration.
The dosing schedule was not ﬁ  xed in advance but deter-
mined for each patient on the basis of their positive (symptom 
reduction) and negative (side-effects) reaction to the drug. 
Milnacipran was taken twice daily, just after getting up 
and just before going to bed in order to reduce the risk of 
disgorging the milnacipran tablets during self-induced vom-
iting. Mosapride, 15 mg/day, could be given to the patients 
with nausea, if necessary.
Standard supportive psychotherapy was provided for 
all patients but no cognitive behavioral therapy was under-
taken.
Analysis
Differences between baseline and post-treatment values 
were assessed by Student’s paired t-test or the Wilcoxon test. 
Tukey’s test was used for multiple comparisons. Correlations 
were tested using Pearson’s correlation coefﬁ  cient test. 
A one-way ANOVA was used to test differences in charac-
teristics among the subgroups of eating disorders.
Results
Characteristics of the subjects
Of the 25 patients recruited, 5 withdrew before the end of 
the study. Two patients chose to stop treatment in favor of 
psychotherapy without reporting any side-effects. Three 
patients complained of severe nausea, which was considered 
probably due to milnacipran and disappeared upon discon-
tinuation of the drug.
Eating disorders with binge eating can be categorized 
as anorexia nervosa, binge-eating/purging type (ANBP), 
bulimia nervosa/purging type (BNP), bulimia nervosa/non-
purging type (BNNP), or binge eating disorder (BED) (APA 
1995). The characteristics of the 20 subjects who completed 
the 8-week study are shown in Table 1. Subjects were 
diagnosed with ANBP, BNP, and BNNP subtypes of eating 
disorders. BED was not found.
There were no signiﬁ  cant differences in characteristics 
between patients with different subtypes of eating disorder 
with the exception of weight and body mass index (BMI). 
One of the 6 patients with anorexia nervosa had no purging 
Table 1 Patient characteristics
 Total  ANBP  BNP  BNNP
Number 20  6  7  7
Age (years)  22.4 ± 4.1  22.17 ± 2.71  22.0 ± 5.3  22.9 ± 4.5
Height (cm)  156.7 ± 5.6  158.3 ± 7.7 155.6  ± 4.7  156.3 ± 6.1
Weight (kg)  48.3 ± 13.5  37.1 ± 5.5* 48.5  ± 4.7  57.6 ± 17.4
Body Mass Index (kg/m2) 19.7  ± 5.2  14.7 ± 1.3** 20.0  ± 1.8  23.5 ± 6.2
Duration of eating disorders (months)  62.9 ± 58.6  60.2 ± 41.2  52.0 ± 61.6  76.1 ± 72.9
Duration of binge episodes (months)  38.9 ± 46.1  45.8 ± 39.6  44.1 ± 58.3  27.6 ± 42.4
Length of previous treatment (months)  21.7 ± 30.4  36.0 ± 32.3  11.0 ± 23.2  20.0 ± 34.4
Values are given as mean ± SD.
Notes: *p = 0.019; **p = 0.009 compared to BNNP.
Abbreviations: ANBP, binge-eating/purging type; BNP, bulimia nervosa/purging type; BNNP, bulimia nervosa/non-purging type.Neuropsychiatric Disease and Treatment 2008:4(1) 297
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episodes. There were thus 12 purgers who vomited regularly, 
and 8 non-purgers who did not.
Milnacipran was administered initially at doses from 
15 to 75 (mean ± SD: 37.0 ± 14.1) mg daily increasing to 
25 to 100 (60.0 ± 22.0) mg daily after 8 weeks. The target 
dose of 100 mg/day was achieved in only 3 patients. Ten 
patients reported some adverse events, judged to be possibly 
related to milnacipran, and 7 patients refused dose increases 
because of fear of possible adverse effects. Of 10 patients 
reporting adverse events, 8 patients complained of nausea, 
2 of dizziness, and 1 a slight fever (1 patient complained of 
both nausea and dizziness).
Improvement of BITE, HAM-D, HAM-A 
and CGI scores
Changes in BITE, HAM-D,HAM-A, and CGI scores 
are shown in Figure 1. Significant improvements were 
found after 1 week on HAM-D, HAM-A, CGI-severity, 
and CGI-improvement scores and after 4 weeks on the 
BITE-symptom scores. At 8 weeks, BITE-symptom, 
HAM-D, HAM-A, CGI-severity, and CGI-improvement 
scores were all signiﬁ  cantly improved from baseline. In 
addition there was a trend (p = 0.065) for improvement on 
the BITE-severity score at 8 weeks. There was no correlation 
between the improvement of BITE scores after 8 weeks and 
the ﬁ  nal dose of milnacipran.
Six items of the BITE-symptom were significantly 
improved after 8 weeks (Table 2). Signiﬁ  cant reduction of 
these items may be interpreted as a reduction in the drive to, 
and regret for, binge eating. In addition there was a trend for 
a reduction in the frequency of binge eating (p = 0.086) and 
the frequency of vomiting (p = 0.083).
BITE score and HAM-D and HAM-A 
scores
There was a signiﬁ  cant positive correlation (r = 0.481, 
p = 0.032) between the improvement of the BITE-symptom 
scores and HAM-A scores after 8 weeks but not between 
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Figure 1 Changes in BITE, HAM-D, HAM-A, and CGI scores. Open columns = baseline − just before ﬁ  rst milnacipran administration; Stippled columns = after 1 week 
administration of milnacipran; Striped columns = after 4 weeks’ administration of milnacipran; Solid columns = 8 weeks’ administration of milnacipran.
Notes: °p   0.1; **p   0.05; ***p   0.01; ****p   0.001 between values indicated.
Abbreviations: BITE, Bulimic Investigatory Test, Edinburgh; CGI, Clinical Global Impression; HAM-D, Hamilton Depression Rating Scale; HAM-A, Hamilton Anxiety Rating Scale.Neuropsychiatric Disease and Treatment 2008:4(1) 298
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the improvement of BITE-symptom scores and HAM-D 
scores. There was no correlation between improvement of 
BITE scores after 8 weeks and HAM-D and HAM-A scores 
at baseline.
BITE score improvement and eating 
disorder subgroups
With the exception of a signiﬁ  cant difference in the improve-
ment of BITE-symptom scores (p = 0.041) after 1 week, there 
were no differences at any time point in the degree of improve-
ment of BITE-symptom or BITE-severity scores in patients 
with anorexia nervosa and those with bulimia nervosa.
At 8 weeks, non-purging patients showed a signiﬁ  cantly 
greater improvement (p = 0.017) in BITE-symptom score 
than purging patients. BITE-severity scores, however, were 
not signiﬁ  cantly different.
BITE score improvement and patient 
background
Age was negatively correlated with bite-severity score at 8 
weeks (r = −0.478, p = 0.033). No other correlations were 
found with BITE scores and weight, BMI, duration of 
eating disorders, duration of binge episodes, or length of 
treatment.
Discussion
Pathological eating attitudes were signiﬁ  cantly improved 
after 4 weeks’ milnacipran administration and there was a 
trend for the frequencies of binge eating and self-induced 
vomiting to decrease after 8 weeks. This is globally similar 
to the results reported previously in 16 patients with bulimia 
nervosa (El-Giamal et al 2003).
Milnacipran signiﬁ  cantly reduced the drive to binge and 
the regret for binge eating, while pathological ideas and 
behaviors common to all patients with eating disorders, such 
as obsession about diet, fear of obesity, eating in hiding, did 
not change. This suggests that milnacipran does not improve 
the fundamental psychopathology of eating disorders but 
only reduces the drive to binge eating.
Depressive mood and anxiety were significantly 
improved after 1 week. In view of the short treatment 
period, however, the possibility of a placebo effect cannot 
be ruled out. The signiﬁ  cant correlation between HAM-A 
and BITE-symptom scores suggests an effect of improved 
eating attitudes on anxiety (or possibly the other way round). 
Eating attitudes and depressive state, however, appear to 
be unrelated.
The reduction of the frequencies of binge eating and 
vomiting after 8 weeks was not statistically signiﬁ  cant. The 
BITE-severity is a relatively crude measure and more pre-
cise results may have been obtained if patients had recorded 
details of their own eating attitudes in addition to using the 
BITE-severity.
Doses of antidepressants, especially SSRI, higher than 
those typically used for depression are thought to be required 
for the effective treatment of bulimia (Carter et al 2003). The 
mean dose of milnacipran that the patients took in this study 
(60 mg per day after 8 weeks) was, however, similar to the 
mean antidepressant dose in Japan. Although there was no 
signiﬁ  cant correlation between the degree of improvement 
in eating attitudes and the dose of milnacipran (possibly as 
a result of the small sample size), it is possible that higher 
doses may have been more effective. In future studies it may 
be useful to consider increasing the dose of milnacipran up 
to 150 or 200 mg/day in patients whose bulimic episodes are 
not sufﬁ  ciently improved, as long as the patient can tolerate 
these doses.
Eleven of the 25 (44%) participants in this study and 8 of 
the 20 (40%) patients who completed the study complained 
of nausea to some extent. While milnacipran has been 
reported to produce fewer gastrointestinal side-effects than 
SSRIs, nausea is a primary side-effect whose severity can be 
reduced by slow titration (Lopez-Ibor et al 1996). The free 
Table 2 Items of the Bulimic Investigatory Test, Edinburgh (BITE)-symptom scale on which the frequency of the answer “yes” (“no” in 
item 13) was signiﬁ  cantly reduced during the 8 week study
Item number  Item content  Reduction from baseline  p
3.  Do you feel a failure if you break your diet once?  25%  0.025
9.  Would you say that food dominated your life?  20%  0.046
10.  Do you ever eat and eat until you are stopped by physical discomfort?  35%  0.008
13.  Can you always stop eating when you want to?  35%  0.020
14.  Do you ever experience overpowering urges to eat and eat and eat?  25%  0.025
20.  Do you turn to food for comfort?  20%  0.046
The other items of the scale were not signiﬁ  cantly modiﬁ  ed from baseline.Neuropsychiatric Disease and Treatment 2008:4(1) 299
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titration allowed by the protocol and the use of mosapride 
may explain why only 3 patients (9%) dropped out because 
of nausea. Patients with eating disorders are particularly 
sensitive to gastrointestinal symptoms and side-effects and 
it is important to start with low doses of milnacipran and 
increase the dose by slow titration, using anti-emetic medica-
tion where necessary.
Eating attitudes were improved to a greater extent in 
patients without purging behavior. This may be related to 
loss of the test drug during vomiting although administration 
times were chosen to reduce this effect.
Milnacipran appears to be effective in the treatment of 
binge eating disorder, which is present in almost half of all 
the patients with eating disorders (Fairburn and Harrisson 
2003). Milnacipran should be tried in patients with binge 
eating episodes even if they have suffered for a long time 
because there its efﬁ  cacy does not seem to be modiﬁ  ed by 
duration of eating disorders or previous treatment.
The present study suffered from a number of weak-
nesses, principally its relatively small sample size, the lack 
of a control group, and the heterogeneity of the sample 
population. In addition the study followed the patients for 
only 8 weeks. The dosing schedule resulted in the use of 
relatively low doses of milnacipran. While ﬂ  exible dos-
ing according to patients´ needs reﬂ  ects routine clinical 
use, it adds to the heterogeneity of the sample. Although 
theoretically the use of higher doses (up to 200 mg/day) 
may have improved the outcome, the inability or refusal of 
most patients to accept higher doses reﬂ  ects the real-world 
limitations of dose escalation in this sensitive population. 
In a future study it would be helpful to monitor milnacip-
ran plasma levels in order to be sure that vomiting did not 
reduce drug absorption. Finally, although the BITE score 
is a useful parameter it is rather crude and the use of more 
detailed measures of eating behavior would ensure a more 
sensitive measure of efﬁ  cacy.
Conclusion
The results of this relatively small open study suggest that 
milnacipran may be effective in the treatment of eating 
disorders with binge eating episodes, reducing drive to 
binge and the regret for binge eating and, to a lesser extent, 
the frequencies of binge eating and vomiting. Milnacipran 
appears to have similar efﬁ  cacy in all subtypes of eating 
disorders studied although patients who purged responded 
less well. A longer-term, placebo-controlled, double-blind 
study of milnacipran in eating disorders with binge eating 
would appear to be justiﬁ  ed.
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